Loading fund…
Loading fund…
| Returns | 1D | 1M | 3M | YTD | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|
| Total return | ▲ +1.2% | ▲ +5.5% | ▲ +12.6% | ▲ +33.5% | ▲ +49.6% | ▲ +82.6% | ▲ +79.5% | ▲ +142.4% |
| Peer average | ▲ +1.2% | ▲ +4.5% | ▲ +9.5% | ▲ +22.6% | ▲ +30.8% | ▲ +76.1% | ▲ +30.8% | — |
| S&P 500 · VOO | ▼ −0.4% | ▲ +0.9% | ▲ +3.3% | ▲ +13.8% | ▲ +13.3% | ▲ +88.8% | ▲ +81.9% | — |
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) operates as an exchange-traded fund. Its primary aim is to mirror the financial performance—both capital appreciation and income generation—of the Nasdaq US Smart Pharmaceuticals Index, prior to any fund-specific fees and expenses. To achieve this, the ETF endeavors to precisely replicate the constituents and their proportionate allocations within that index, striving for a performance correlation of at least 95%.
Distribution yield and SEC yield use different methodologies. Payouts may include income, capital gains, or return of capital.
| Ex-date | Pay date | Per share |
|---|---|---|
| 2026-09-24 | 2026-09-30 | $0.01 |
| 2026-06-25 | 2026-06-30 | $0.09 |
| 2026-03-26 | 2026-03-31 | $0.06 |
| 2025-12-12 | 2025-12-31 | $0.13 |
| 2025-09-25 | 2025-09-30 | $0.15 |
| 2025-06-26 | 2025-06-30 | $0.09 |
| 2025-03-27 | 2025-03-31 | $0.10 |
| 2024-12-13 | 2024-12-31 | $0.13 |
| 2024-09-26 | 2024-09-30 | $0.12 |
| 2024-06-27 | 2024-06-28 | $0.13 |
| 2024-03-21 | 2024-03-28 | $0.07 |
| 2023-12-22 | 2023-12-29 | $0.12 |
Estimated annual expense excludes trading costs and assumes constant assets. Fee waivers and fund costs can change.
Historical risk measures describe past behavior and do not predict future returns.
Hear the strategy from the people behind FTXH.